EGFR mutation testing of lung cancer patients – Experiences from Vestfold Hospital Trust

References

• Cancer in Norway 2012. Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2014. p. 97.
   Google Scholar
• Brustugun OT, Moller B, Helland A. Years of life lost as a measure of cancer burden on a national level. Br J Cancer 2014;111:1014–20.
   PubMed Web of Science ®Google Scholar
• Sagerup CMT, Smastuen M, Johannesen TB, Helland A, Brustugun OT. Sex-specific trends in lung cancer incidence and survival: A population study of 40,118 cases. Thorax 2011;66:301–7.
   PubMed Web of Science ®Google Scholar
• Helbekkmo N, Sundstrom SH, Aasebo U, Brunsvig PF, von Plessen C, Hjelde HH, et al. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 2007;97:283–9.
   PubMed Web of Science ®Google Scholar
• Grønberg BH, Bremnes RM, Fløtten Ø, Amundsen T, Brunsvig PF, Hjelde HH, et al. Phase III study by the Norwegian lung cancer study group: Pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:3217–24.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Engl J Med 2009;361:947–57.
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. New Engl J Med 2010;362: 2380–8.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327–34.
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239–46.
   PubMed Web of Science ®Google Scholar
• Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. New Engl J Med 2009;361:958–67.
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Wu Y-L, Thongprasert S, Sunpaweravong P, Leong S-S, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866–74.
   PubMed Web of Science ®Google Scholar
• Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): A randomised controlled trial. Lancet Oncol 2013;14:981–8.
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Binder A, Jänne PA. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 2013;31:1097–104.
   PubMed Web of Science ®Google Scholar
• Herth FJF, Bubendorf L, Gutz S, Morresi-Hauf A, Hummel M, Junker K, et al. [Diagnostic and predictive analyses of cytological specimens of non-small cell lung cancer: strategies and challenges]. Pneumologie 2013;67:198–204.
   PubMedGoogle Scholar
• Warth A, Bubendorf L, Gutz S, Morresi-Hauf A, Hummel M, Junker K, et al.[Molecular pathological diagnosis in cytopathology of non-small-cell lung cancer. Standardization of specimen processing]. Pathologe 2013;34:310–7.
   PubMed Web of Science ®Google Scholar
• Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013;8:823–59.
   PubMed Web of Science ®Google Scholar
• Brustugun O, Helland Å, Fjellbirkeland L, Kleinberg L, Ariansen S, Jebsen P, et al. [Mutation testing for non-small-cell lung cancer]. Tidsskr Nor Laegeforen 2012;132:952–5.
   PubMedGoogle Scholar
• Ellison G, Zhu G, Moulis A, Dearden S, Speake G, McCormack R. EGFR mutation testing in lung cancer: A review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol 2013;66:79–89.
   PubMed Web of Science ®Google Scholar
• Hagiwara K, Kobayashi K. Importance of the cytological samples for the epidermal growth factor receptor gene mutation test for non-small cell lung cancer. Cancer Sci 2013;104:291–7.
   PubMed Web of Science ®Google Scholar
• Jurado J, Saqi A, Maxfield R, Newmark A, Lavelle M, Bacchetta M, et al. The efficacy of EBUS-guided transbronchial needle aspiration for molecular testing in lung adenocarcinoma. Ann Thorac Surg 2013;96:1196–202.
   PubMed Web of Science ®Google Scholar
• Khode R, Larsen DA, Culbreath BC, Parrish S, Walker KL, Sayage-Rabie L, et al. Comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas. Cancer Cytopathol 2013;121:361–9.
   PubMed Web of Science ®Google Scholar
• Skov BG, Hogdall E, Clementsen P, Krasnik M, Larsen KR, Sorensen JB, et al. The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population. Acta Pathol Microbiol Immunol Scand 2015;123:108–15.
   PubMed Web of Science ®Google Scholar
• Helland Å, Skaug HM, Kleinberg L, Iversen ML, Rud AK, Fleischer T, et al. EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery. J Thorac Oncol 2011;6:947–50.
   PubMed Web of Science ®Google Scholar
• Kleinberg L, Jebsen P, Lund-Iversen M, Helland A, Fjellbirkeland L. EGFR-mutated lunge cancer in a general Norwegian population. In: (ERS) ERS, editor. European Respiratory Society (ERS) International Congress 6–10 September 2014 Germany, Bayern, Munich.
   Google Scholar
• Barlesi F, Blons H, Beau-Faller M, Rouquette I, Ouafik L, Mosser J, et al. Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol 2013;1.
   Google Scholar
• Pang B, Dettmer M, Ong CW, Dhewar AN, Gupta S, Lim GL, et al. The positive impact of cytological specimens for EGFR mutation testing in non-small cell lung cancer: A single South East Asian laboratory's analysis of 670 cases. [Erratum appears in Cytopathology 2012;23:422. Note: Matthias, D (corrected to Dettmer, M)]. Cytopathology 2012;23:229–36.
   PubMed Web of Science ®Google Scholar
• Twaddell S, Cox Y. A single centre review of endothelial growth factor receptor (EGFR) mutation testing: A regional Australian experience. J Thorac Oncol 2013;8:S1025–6.
   Google Scholar
• Subramonia Iyer S, Olsen B, Hrinczenko B. Biopsy method and sample adequacy for molecular testing in advanced non small cell lung cancer. J Thorac Oncol 2012;4:S307–8.
   Google Scholar
• Krawczyk P, Ramlau R, Chorostowska-Wynimko J, Powrozek T, Lewandowska MA, Limon J, et al. The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: A multicenter retrospective study. J Cancer Res Clin Oncol 2015;141:61–8.
   PubMed Web of Science ®Google Scholar
• Patton S, Normanno N, Blackhall F, Murray S, Kerr KM, Dietel M, et al. Assessing standardization of molecular testing for non-small-cell lung cancer: Results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing. Br J Cancer 2014;111:413–20.
   PubMed Web of Science ®Google Scholar
• Jurado J, Saqi A, Maxfield R, Newmark A, Lavelle M, Bacchetta M, et al. The efficacy of EBUS-guided transbronchial needle aspiration for molecular testing in lung adenocarcinoma. Ann Thorac Surg 2013;96:1196–202.
   PubMed Web of Science ®Google Scholar
• Murgu S, Colt H. Role of the pulmonologist in ordering post-procedure molecular markers in non-small-cell lung cancer: Implications for personalized medicine. Clin Lung Cancer 2013;14:609–26.
   PubMed Web of Science ®Google Scholar